Literature DB >> 2826847

Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver.

T Nakajima1, N Mizushima, K Kanai.   

Abstract

Natural killer (NK) activities of peripheral blood lymphocytes (PBL) in 50 patients with non-alcoholic liver cirrhosis (LC) were prospectively studied in order to clarify the relation between the development of hepatocellular carcinoma (HCC) and impaired NK activities. Patients were divided into two groups according to their NK activities at the beginning of the study, namely, Group A with normal NK activity (n = 21) and Group B with decreased NK activity (n = 29). NK activities were serially determined in each patient for up to 40 months. During the observation period, the occurrence of HCC was identified in 12 patients (four to 36 months). Of the patients who developed HCCs, two belonged to Group A (9.5%) and 10 belonged to Group B (34.5%). These results suggest decreased NK activity in LC patients to be one of the critical factors increasing their risk of developing HCC, and serial determinations of NK activities to be important in predicting the occurrence of HCCs in following the clinical course of LC patients.

Entities:  

Mesh:

Year:  1987        PMID: 2826847

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  12 in total

1.  Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma.

Authors:  Kazuko Uno; Yoshiki Suginoshita; Kazuhiro Kakimi; Fuminori Moriyasu; Mayumi Hirosaki; Taro Shirakawa; Tsunataro Kishida
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells.

Authors:  Gavin E Arteel
Journal:  Gastroenterology       Date:  2008-01       Impact factor: 22.682

3.  Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study.

Authors:  Jennifer L Steel; Kevin H Kim; Mary Amanda Dew; Mark L Unruh; Michael H Antoni; Marion C Olek; David A Geller; Brian I Carr; Lisa H Butterfield; T Clark Gamblin
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

4.  Natural killing activities in chronic liver diseases and hepatocellular carcinoma.

Authors:  K Ono; Y Yamanaga; K Yamamoto; S I Koga; J Nishimura; H Nawata
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

5.  A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma.

Authors:  Xiao-Feng Li; Dong Dai; Xiu-Yu Song; Jian-Jing Liu; Lei Zhu; Xiang Zhu; Wenchao Ma; Wengui Xu
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

Review 6.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.

Authors:  Cheng Sun; Haoyu Sun; Cai Zhang; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2014-10-13       Impact factor: 11.530

Review 7.  Psychosocial stress and liver disease status.

Authors:  Cristin Constantin Vere; Costin Teodor Streba; Letitia Maria Streba; Alin Gabriel Ionescu; Felix Sima
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

8.  Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study.

Authors:  Ryoko Sawamoto; Jun Nagano; Eiji Kajiwara; Junko Sonoda; Tetsuya Hiramoto; Nobuyuki Sudo
Journal:  Biopsychosoc Med       Date:  2016-07-29

9.  CAM and NK Cells.

Authors:  Kazuyoshi Takeda; Ko Okumura
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

Review 10.  Does Natural Killer Cell Deficiency (NKD) Increase the Risk of Cancer? NKD May Increase the Risk of Some Virus Induced Cancer.

Authors:  Won Young Moon; Simon J Powis
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.